Brandenburg Kapital - News about Adrenomed AG
Adrenomed presented positive results of the phase II study with the antibody Adrecizumab in septic shock at e-ISICEM symposium
Potsdam/Hennigsdorf - September 2020. Adrenomed AG, a pharmaceutical company focused on restoring the vascular integrity of blood vessels, presented positive results of the phase II clinical trial at the sepsis session during e-ISICEM, the International Symposium on Intensive Care and Emergency Medicine, on September 16th 2020.
The phase 2 study confirmed the safety and tolerability of the vaso-stabilizing antibody Adrecizumab in patients with early septic shock. Furthermore, Adrecizumab demonstrated a significant and fast improvement of organ function and a substantial reduction on short-term mortality in the biomarker-guided trial. The mode of action was also confirmed in this trial: Adrecizumab rapidly increased plasma levels of Adrenomedullin, a key hormone maintaining and restoring vascular integrity and endothelial function.
About Adrenomed
Adrenomed AG is a German privately financed, clinical-stage biopharmaceutical company. Adrenomed’s mission is to rescue vascular integrity in order to save the lives of critically ill patients with limited treatment options. Founded in 2009 by a management team with decades of in-depth experience in sepsis and deep knowledge in diagnostics and drug development, the company’s lead product candidate Adrecizumab is a first-in-class monoclonal antibody. Adrecizumab targets the vasoprotective peptide Adrenomedullin, an essential regulator of vascular integrity. Adrecizumab has successfully completed a biomarker-guided, double-blinded, placebo-controlled, randomized, multicenter proof-of-concept Phase II trial with 301 patients suffering from septic shock.
For further information, please visit www.adrenomed.com and www.brandenburg-kapital.de
